Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Tale of two eye drugs plays out in Medicare's doctor reimbursements

Behind ophthalmology's recent ranking as Medicare's highest-reimbursed specialty is a tale of two eye drugs.

Lucentis and Avastin have been shown equally effective in combating age-related macular degeneration, the leading cause of blindness in the elderly. They share a similar molecular make-up and even the same manufacturer.

But the cost per dose is much different: $2,000 versus $50. With a recommended two-year, 24-injection course of treatment, the difference per patient is huge.

Ophthalmologists, who buy the drugs and are then reimbursed for them, used the pricier Lucentis often enough to account for about $1 billion in Medicare spending in 2012, according to recently released data from Centers for Medicare and Medicaid Services. Indeed, Lucentis is a key reason ophthalmologists are at the top of the Medicare list.

Critics say the way doctors are reimbursed under Medicare — the average cost of the drug, plus 6 percent of the cost — sets up a financial incentive to choose the costlier medication. An Ohio ophthalmologist who has been outspoken on the debate, Dr. J. Gregory Rosenthal, said doctors shouldn't use Lucentis.

"It has no reason to exist," said Rosenthal. "No medical reason. Of course, it has an economic reason."

Other physicians say it's more complicated.

Only the pricier Lucentis has federal approval for the treatment of eye disease. Avastin is approved as a cancer drug, but a South Florida doctor in 2005 showed it could be effective for macular degeneration. Later, a two-year study by the National Institutes of Health confirmed the drugs are equally effective.

Such an "off-label" use of a drug isn't unusual, but it can give some patients pause, said Dr. Mark Hammer, a Tampa ophthalmologist with among the highest Medicare reimbursements in the area. His practice uses Lucentis more often than Avastin.

Compounding pharmacies take large vials of Avastin made for cancer patients and divide them into the tiny portions used in the eyes. Cases involving dirty medications coming out of compounding pharmacies — including a dozen Miami-area patients in 2011 who suffered eye inflammation and blindness from a contaminated batch of Avastin — hurt the industry's reputation and raised fears of infection.

"Compounding pharmacies are not well regulated, and there have been some horrendous cases of blindness reported," said Dr. Peter Pavan, chairman of the ophthalmology department at the University of South Florida's Morsani School of Medicine.

Yet, he noted, problems have been rare compared with how often the drug is used. He said patients at USF Eye Institute chose the two drugs at roughly the same frequency. Patients pick Avastin because of the cost.

"Avastin is enormously safe, enormously effective and cost effective," he said. "For many patients it's a Godsend."

• • •

Data released last week covered only those patients in traditional Medicare, not the roughly one-third of recipients enrolled in privately managed Medicare Advantage plans. Though patients on traditional Medicare owe 20 percent co-insurance for the drug, supplemental policies may cover much of that share.

"Avastin is much less expensive, but if Lucentis is paid for by their insurance company to them it doesn't make a difference," said Hammer. "Sometimes they say, 'Well I want to save the government money.' But not often."

Medicare is forbidden by law to tell doctors to use a less expensive drug. A bigger issue: The federal program cannot negotiate with pharmaceutical companies for lower prices.

Pavan said it's not clear that there is a financial incentive to use Lucentis. When patients don't pay their share, the practice eats the cost. If Medicare balks at paying for a treatment, the doctor has no hope of reimbursement. And the automatic budget cuts known as the sequester take some of that 6 percent, he said, meaning that Lucentis isn't necessarily a lucrative choice.

He said the idea that doctors chose Lucentis for their own financial gain is "ludicrous."

• • •

Physicians and the government have long known about this issue. A September 2011 report from the federal Office of Inspector General found that if doctors used Avastin rather than Lucentis, the Medicare program would have saved $1.4 billion.

Both drugs work by blocking growth of abnormal blood vessels and leakage of fluid that create the damage seen in age-related macular degeneration, also known as the "wet'' form of the condition.

Genentech developed Avastin for cancer. It has not sought approval of it as an eye medication, despite the FDA's encouragement, according to the Washington Post.

While Avastin is very expensive for cancer patients, it's cheap for eye patients because such a small dosage is required. So Genentech can make far more money off Lucentis for eye care.

The National Institutes of Health's two-year clinical trial, ending in 2012, found the drugs were similarly effective among patients in the study, whose average age was 80. The Avastin patients were more likely to suffer "adverse events" that required hospitalization, but the study could not detect a link between the drugs used and the need to go to the hospital.

Jodie Tillman can be reached at [email protected] or (813) 226-3374.

Tale of two eye drugs plays out in Medicare's doctor reimbursements 04/15/14 [Last modified: Tuesday, April 15, 2014 11:34pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times


Join the discussion: Click to view comments, add yours

  1. Tampa Bay small businesses give Tampa B+ for regulatory climate


    In a recent survey about small business sentiments toward state and local government policies that affect them, Tampa Bay ranked at No. 25 out of 80 — a B+ overall.

    Tampa Bay ranked No. 25 out of 80 in a recent survey about how small business owners feel about state and local government policies that affect them. | [Times file photo]
  2. Dirk Koetter to Bucs: Take your complaints to someone who can help


    TAMPA — It was just another day of aching bellies at One Save Face.

    Dirk Koetter: “All of our issues are self-inflicted right now.”
  3. Seminole Heights murders: fear and warnings, but no answers


    TAMPA — Interim Tampa police Chief Brian Dugan elicited loud gasps from the crowd of about 400 who showed up at Edison Elementary School on Monday night to learn more about the string of unsolved killings that have left the southeast Seminole Heights neighborhood gripped by fear.

    Kimberly Overman, left, comforts Angelique Dupree, center, as she spoke about the death of her nephew Benjamin Mitchell, 22, last week in Seminole Heights. The Tampa Police Department held a town hall meeting Monday night where concerned residents hoped to learn more about the investigation into the three shooting deaths over 11 days in southeast Seminole Heights. But police could give the crowd at Edison Elementary School few answers. [OCTAVIO JONES   |   Times]
  4. Juvenile justice reform seen as help for teen car theft problem


    ST. PETERSBURG — One of Tampa Bay's largest religious organizations has decided to make reforming the juvenile justice system one of its top priorities for next year.

    One of Tampa Bay's largest religious organizations, Faith & Action for Strength Together (FAST), voted Monday night to make reforming the juvenile justice system one of its top priorities for next year. FAST believes civil citations could help Pinellas County?€™s teen car theft epidemic by keeping children out of the juvenile justice system for minor offenses. [ZACHARY T. SAMPSON  |  Times]
  5. U.S. general lays out Niger attack details; questions remain (w/video)


    WASHINGTON — The U.S. Special Forces unit ambushed by Islamic militants in Niger didn't call for help until an hour into their first contact with the enemy, the top U.S. general said Monday, as he tried to clear up some of the murky details of the assault that killed four American troops and has triggered a nasty …

    Gen. Joseph Dunford said much is still unclear about the ambush.